Available influenza vaccines: immunization strategies, history and new tools for the fight against the disease


Influenza vaccines
immunization strategies
quadrivalent influenza vaccine


The main public health strategy for containing influenza-related disease is annual vaccination, which is recommended for the elderly and others belonging to risk-factor categories, that present the highest morbidity and mortality, as reported by the World Health Organization (WHO) Recommendations.

The availability of different influenza vaccine formulations make the choice of the best immunization strategy a challenge for stakeholders and public health experts.

Heterogeneity in at-risk categories included in national influenza vaccine recommendations still exists, in particular among European Countries. A wider consensus is expected, in order to positively impact on influenza vaccination coverage.

The availability of quadrivalent vaccines, containing both influenza B lineages, offers the potential of improved protection, overcoming the drawbacks of wrongly predicting which B lineage will predominate in a given year.



Parodi V, Florentiis, D. de , Martini M, Ansaldi F. Inactivated influenza vaccines: recent progress and implication for the el- derly. Drugs Aging 2011;1;28(2):93-106. Available from: http://link.springer.com/10.2165/11586770-000000000-00000 doi: 10.2165/11586770-000000000-00000. [Google Scholar]

Hannoun C. The evolving history of influenza viruses and influ- enza vaccines. Expert Rev Vaccines 2013;12(9):1085-94. Available from: http://www.tandfonline.com/doi/full/10.1586/14760584.2013.824709 doi: 10.1586/14760584.2013.824709. [Google Scholar]

Wood JM, Williams MS. History of Inactivated Influenza vac- cines. In: Textbook of Influenza. Oxford: Blackwell Science; 1998. [Google Scholar]

Florentiis, D. de , Parodi V, Rossi A, Altomonte F, Canepa P, Ceravolo A, et al. Impact of influenza during the post-pan- demic season: epidemiological picture from syndromic and vi- rological surveillance. J Prev Med Hyg 2011;52:134-6. [Google Scholar]

Crovari P, Alberti M, Alicino C. History and evolution of influ- enza vaccines. J Prev Med Hyg 2011;52:91-4. [Google Scholar]

Haaheim LR, Madhun AS, Cox R. Pandemic influenza vaccines – the challenges. Viruses 2009 Dec;1(3):1089-1109. Available from: http://www.mdpi.com/resolver?pii=viruses-01-01089 PubMed PMID: 21994584. doi: 10.3390/v1031089. [Google Scholar]

Treanor JJ. Prospects for broadly protective influenza vaccines. Vaccine 2015;33(Suppl 4):4-39. [Google Scholar]

Gasparini R, Amicizia D, Lai PL, Panatto D. Live attenuated influenza vaccine--a review.. J Prev Med Hyg 2011;52(3):95-101. PubMed PMID: 22010534. [Google Scholar]

Sridhar S, Brokstad KA, Cox RJ. Influenza vaccination strate- gies: comparing inactivated and live attenuated influenza vac- cines. Vaccines 2015;3(2):373-89. Available from: http://www.mdpi.com/2076-393X/3/2/373 doi: 10.3390/vaccines3020373. [Google Scholar]

Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Monto- moli E, , et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemag- glutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008;26(12):1525-9. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0264410X08000777 doi: 10.1016/j.vaccine.2008.01.019. [Google Scholar]

Minutello M, Senatore F, Cecchinelli G, Bianchi M, Andreani T, Podda A, et al. Safety and immunogenicity of an inac- tivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in helderly subjects, immunized for three consecutive influenza Seasons. Vaccine 1999;17(2):99-104. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0264410X98001856 doi: 10.1016/S0264-410X(98)00185-6. [Google Scholar]

Giudice, G. Del , Hilbert AK, Bugarini R, Minutello A, Popova O, Toneatto D, et al. An MF59-adjuvanted inactivated vaccine containing A/ Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 2006;24(16):3063-5. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0264410X06000272 doi: 10.1016/j.vaccine.2006.01.015. [Google Scholar]

Gasparini R, Pozzi T, Montomoli E, Fragapane E, Senatore F, Minutello M, et al. Increased immunogenicity of the MF59- adjuvanted vaccine compared to a conventional vaccine in el- derly subjects. Eur J Epidemiol 2001;17:135-40. [Google Scholar]

Arakane R, Annaka R, Takahama A, Ishida K, Yoshiike M, Na- kayama T, , et al. Superior immunogenicity profile of the new intradermal influenza vaccine compared to the standard subcutaneous vaccine in subjects 65 years and older: a rand- omized controlled phase III study. Vaccine 2015;33(48):6650-8. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0264410X15015315 doi: 10.1016/j.vaccine.2015.10.088. [Google Scholar]

Assen, S. van , Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70(3):414-422. Available from: http://www.scholaruniverse.com/ncbi-linkout?id=21131643 PubMed PMID: 21131643. doi: 10.1136/ard.2010.137216. [Google Scholar]

Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Baddour LM, Dunbar S, Krumholz HM , Association AH, Cardiology ACo, Rehabilitation AAoCaP, Nurses AAoCC, Nurses AAoHF, et al. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology.. . Available from: http://www.ncbi.nlm.nih.gov/pubmed/17010820 PubMed PMID: 17010820. [Google Scholar]

Kobashigawa,T,InoueE,TanakaE,MomoharaS,YamanakaH . Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observa- tional cohort. Scand J Rheumatol 2013;42(6):445-50. Available from: http://www.tandfonline.com/doi/full/10.3109/03009742.2013.788733 doi: 10.3109/03009742.2013.788733. [Google Scholar]

Westra J, Rondaan C, Assen, S. van , Bijl M. Vaccination of pa- tients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol 2015;11(3):135-45. Available from: http://www.nature.com/doifinder/10.1038/nrrheum.2014.206 doi: 10.1038/nrrheum.2014.206. [Google Scholar]

Baluch A, Pasikhova Y. Influenza vaccination in oncology pa- tients. Curr Infect Dis Rep 2013;15(6):486-90. Available from: http://link.springer.com/10.1007/s11908-013-0368-7 doi: 10.1007/s11908-013-0368-7. [Google Scholar]

CaldeiraD,CostaJ,Vaz-CarneiroA . AnalysisoftheCochrane review: influenza Vaccines for preventing cardiovascular dis- ease. Cochrane Database Syst Rev 2015;5:CD00505. Acta Med Port 2015;28(4):424-6. Available from: http://actamedicaportuguesa.com/revista/index.php/amp/article/view/6846 doi: 10.20344/amp.6846. [Google Scholar]

GrohskopfLA,SokolowLZ,OlsenSJ,BreseeJS,BroderKR, Karron RA . Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immuniza- tion Practices, United States, 2015-16 Influenza Season. Am J Transplant 2015;15(10):2767-75. Available from: http://doi.wiley.com/10.1111/ajt.13505 doi: 10.1111/ajt.13505. [Google Scholar]

Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, McGeer AJ, Neuzil KM, Pavia AT, Tapper ML, Uyeki TM, Zimmerman RK, , America, P.o.t.I.D.S.o. (Expert) . Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and in- stitutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009 Apr;48(8):1003-1032. Available from: http://www.cid.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=19281331 PubMed PMID: 19281331. doi: 10.1086/598513. [Google Scholar]

Seasonal influenza vaccination recommendations in Europe. Available at: http://ecdc.europa.eu/en/publications/Publica- tions/Seasonal-influenza-vaccination-Europe-2012-13.pdf. [Accessed 18/01/16].

Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, Cox NJ, , Centers for Disease Control and Prevention (CDC . Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59(RR-8):1-62. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5908a1.htm PubMed PMID: 20689501. [Google Scholar]

European Centre for Disease Prevention and Control (ECDC). ECDC scientific advice on seasonal influenza vaccination of children and pregnant women. Stockholm: ECDC 2012. Avail- able at: http://www.ecdc.europa.eu/en/publications/Publications/ Seasonal%20influenza%20vaccination%20of%20children%20 and%20pregnant%20women.pdf. [Accessed 18/01/16].

European Medicines Agency (EMA). Fluenz influenza vaccine (live attenuated, nasal). Summary of opinion1 (initial authorisation). October 2010. London: EMA 2010. EMA/CHMP/503333/2010. Available from: http://www.ema.europa.eu/docs/en_GB/docu- ment_library/Summary_of_opinion_-_Initial_authorisation/hu- man/001101/WC500098347.pdf [Accessed 18/01/16].

Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, et al. I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe.. . Available from: http://www.ncbi.nlm.nih.gov/pubmed/22110695 PubMed PMID: 22110695. doi: 10.1371/journal.pone.0027622.

Kissling E, Valenciano M. Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study.. Euro Surveill 2011 Mar;16(11). Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19818 PubMed PMID: 21435329. [Google Scholar]

Centers for Disease Control and Prevention (CDC . Intensive- care patients with severe novel influenza A (H1N1) virus infec- tion - Michigan, June 2009. MMWR Morb Mortal Wkly Rep 2009;58:749-52. [Google Scholar]

LouieJK,AcostaM,SamuelMC,SchechterR,VugiaDJ,Har- riman K, Matyas BT, , California Pandemic (H1N1) Working Group . A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1. Clin Infect Dis 2011;52(3):301-12. Available from: http://cid.oxfordjournals.org/lookup/doi/10.1093/cid/ciq152 doi: 10.1093/cid/ciq152. [Google Scholar]

Morgan OW, Bramley A, Fowlkes A, Freedman DS, Taylor TH, Gargiullo P, et al. Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease.. . Available from: http://www.ncbi.nlm.nih.gov/pubmed/20300571 PubMed PMID: 20300571. doi: 10.1371/journal.pone.0009694.. [Google Scholar]

on season- al influenza vaccination. Official journal of the European Union. Available at: http://eur-lex.europa.eu/legal-content/EN/ TXT/?uri=CELEX:32009H1019. [Accessed 18/01/16. Council Recommendation of 2009;22. [Google Scholar]

EuropeanCentersforDiseaseControlandPrevention(ECDC). Seasonal Influenza Vaccination Programme in Italy. Available at: http://ecdc.europa.eu/en/publications/Report%20Assets/ seasonal-vaccination-coverage-in-europe-2012-13/Seasonal- Influenza-Vaccination-Programme-Country-Profile-Italy.pdf. [Accessed 18/01/16].

Bonanni P, Ferro A, Guerra R, Iannazzo S, Odone A, Pompa MG, et al. Vaccine coverage in Italy and as- sessment of the 2012-2014 National Immunization Prevention Plan. Epidemiol Prev 2015;39(4 Suppl 1):146-58. [Google Scholar]

Crépey P, Boer, P.T. de , Postma MJ, Pitman R. Retrospective public health impact of a quadrivalent influenza vaccine in the United States. Influenza Other Respir Viruses 2015;9(Suppl 1):39-46. Available from: http://dx.doi.org/10.1111/irv.12318 PubMed PMID: 26256294. doi: 10.1111/irv.12318. [Google Scholar]

LangleyJM,CarmonaMartinezA,ChatterjeeA,HalperinSA, McNeil S, Reisinger KS, Aggarwal N, Huang LM, Peng CT, Garcia-Sicilia J, Salamanca de la Cueva I, Cabañas F, Treviño- Garza C, Rodríguez-Weber MA, de la O M, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK . Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis 2013;208(4):544-53. Available from: http://jid.oxfordjournals.org/lookup/doi/10.1093/infdis/jit263 doi: 10.1093/infdis/jit263. [Google Scholar]

Block SL, Falloon J, Hirschfield JA, Halperin SA, McNeil S, Reisinger KS, et al. Immunogenicity and safety of a quadriva- lent live attenuated influenza vaccine in children. Pediatr Infect Dis 2012;31:745-51. [Google Scholar]

Pépin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M. Safety and immunogenicity of a quadrivalent inactivated influ- enza vaccine in adults. Vaccine 2013;31(47):5572-8. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0264410X1301181X doi: 10.1016/j.vaccine.2013.08.069. [Google Scholar]

Thommes EW, Ismaila A, Chit A, Meier G, Bauch CT. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.. BMC Infect Dis 2015 Oct;15(1):465. Available from: http://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-015-1193-4 PubMed PMID: 26503131. doi: 10.1186/s12879-015-1193-4. [Google Scholar]